AstraZeneca - Q1 2026 Earnings Analysis

Performance Highlights

AstraZeneca reported Q1 2026 total revenue of $15.3 billion, an 8% increase at constant exchange rates, beating consensus expectations on the top line with core operating profit growing 12% to $5.4 billion. Core EPS of $2.58 rose 5%, modestly constrained by a favourable prior-year tax rate, while the core gross margin expanded one percentage point to 83%.

Oncology was the primary growth engine, with segment revenue surging 16% to $6.8 billion on broad-based demand; Imfinzi grew 30%, Enhertu 34%, Calquence 17%, and Truqap 47%, collectively more than offsetting a 6% decline in CVRM driven by Farxiga VBP implementation in China and Brilinta generic competition. Rare Disease rose 15% to $2.4 billion, led by Ultomiris at +18%, while BioPharmaceuticals R&I grew 7% with Tezspire up 34% and Breztri up 13%.

Management Outlook and Forward Catalysts

Management reiterated FY 2026 guidance for mid-to-high single-digit total revenue growth and low double-digit core EPS growth at CER, signalling confidence in commercial momentum despite CVRM headwinds and increasing R&D investment, with active clinical trial patient enrolment up 30% year-on-year. Four positive Phase III readouts — tozorakimab in COPD, efzimfotase alfa in HPP, Imfinzi plus Imjudo in locoregional HCC, and Ultomiris in IgAN — materially reinforce the company's $80 billion 2030 revenue ambition.

The central investor debate for next quarter centres on the pace and magnitude of Farxiga generic erosion in the US market following April entry, the commercial trajectory of Baxdrostat ahead of its Q2 PDUFA date, and whether tozorakimab's Phase III COPD data translates into a regulatory filing timeline consistent with the $3–5 billion peak-year revenue target. Bulls will watch ASCO data catalysts and Calquence AMPLIFY uptake in Europe, while bears will scrutinise CVRM deterioration and rising SG&A from pre-launch investment.